
News|Videos|June 24, 2024
Osimertinib (osi) After Definitive Chemoradiotherapy (CRT) in Patients (pts) With Unresectable Stage (stg) III Epidermal Growth Factor Receptor-Mutated (EGFRm) NSCLC: Primary Results of the Phase 3 LAURA Study
The LAURA study (NCT03521154) evaluates the efficacy and safety of Osimertinib as a maintenance therapy following chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer
2
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
3
Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
4
ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention
5





















































